Symbols

ATRC

AtriCure·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 5

Bearish signal 0

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ATRC

Atricure, Inc.

A leading innovator in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management

Industry

Healthcare Equipment and Supplies

Established Date

10/31/2000

Listing Date

08/05/2005

Exchange

NASDAQ Stock Exchange

Full-time Employees

1,300

Fiscal Year Ends

12-31

Website

www.atricure.com

Security Type

Common stock

Office address

7555 Innovation Way , Mason , OH 45040

Business

Introduction

AtriCure, Inc., a medical device company, provides innovative atrial fibrillation solutions to reduce the economic and social burden of atrial fibrillation, achieving superior results. The company's synergistic ablation system is the first and only device approved by the U.S. Food and Drug Administration for the treatment of long-lasting atrial fibrillation. The company has two main product lines in the ablation of cardiac tissue. The company's main product line is the ablation of cardiac tissue, which accounts for the vast majority of the company's revenue, the collaborative system bipolar ablation forceps system and related radiofrequency ablation equipment. The company also offers a frozen product line that features reusable equipment and one-time freezing. The company's AtriClip system is the world's most widely used implant for left atrial appendage management. The company believes that cardiothoracic surgeons using the company's ablation and left atrial appendage management device can reduce AFIB-related complications in the treatment of AFIB. The company was incorporated in Delaware on October 31, 2000. The company is a leading partner in atrial fibrillation solutions, providing innovative products, professional education, and supporting clinical science to reduce the economic and social burden of AFIB. The company sells its products to hospitals worldwide through a direct sales force and distributors.

Earnings Call

Q2/2025

Estimate EPS-0.16

Actual EPS-0.13

Estimate Revenue130.17M

Actual Revenue136.10M

AtriCure's Q2 2025: Navigating Contradictions in MIS Business, PFA Pressures, and Market Outlook

Jul 29,2025 07:39·
Earnings Decrypt

Q3/2025

Estimate EPS-0.12

Actual EPS-0.01

Estimate Revenue131.25M

Actual Revenue134.30M

AtriCure's Q3 2025: Contradictions Emerge in PFA Timelines, CryoXT Launch, and U.S. MIS Recovery

Oct 29,2025 11:52·
Earnings Decrypt

Company Financials

EPS

ATRC has released its 2025 Q3 earnings. EPS was reported at -0.01, versus the expected -0.12, beating expectations. The chart below visualizes how ATRC has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ATRC has released its 2025 Q3 earnings report, with revenue of 134.27M, reflecting a YoY change of 15.84%, and net profit of -267.00K, showing a YoY change of 96.60%. The Sankey diagram below clearly presents ATRC's revenue sources and cost distribution.